Genetically changed mice with chronic deficiency or overexpression of the β-adrenoceptors - What can we learn for the therapy of heart failure?

Pflugers Archiv European Journal of Physiology

Volumn 455, Issue 5, 2008, Pages 767-774

  Lee, Samuel ^a,b   Schwinger, Robert H G ^a,b   Brixius, Klara ^a,c  

^a UNIVERSITY OF COLOGNE   (Germany)

^b Hospital Weiden   (Germany)

^c GERMAN SPORT UNIVERSITY COLOGNE   (Germany)

Author keywords

Beta 1 adrenoceptor; Beta 2 adrenoceptor; Beta 3 adrenoceptor; Heart failure; Knockout; Mice; Overexpression

Indexed keywords

3 ISOPROPYLAMINO 1 (7 METHYL 4 INDANYLOXY) 2 BUTANOL; BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; BETA 3 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUPRANDOLOL; CALCIUM ION; FREE RADICAL; NADOLOL; NITRIC OXIDE; PHOSPHOLAMBAN; UNCLASSIFIED DRUG;

ADRENERGIC SYSTEM; APOPTOSIS; BETA ADRENERGIC STIMULATION; CALCIUM SIGNALING; CARDIOTOXICITY; CARDIOVASCULAR SYSTEM; DNA MODIFICATION; GENE DELETION; HEART FAILURE; HEART FUNCTION; HEART INFARCTION; HEART INFARCTION SIZE; HEART MUSCLE CONTRACTILITY; HEART VENTRICLE HYPERTROPHY; HUMAN; INOTROPISM; KNOCKOUT MOUSE; MOUSE; NEGATIVE FEEDBACK; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN FUNCTION; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION; REVIEW; TRANSGENIC MOUSE; TREATMENT OUTCOME;

ANIMALS; CHRONIC DISEASE; DISEASE MODELS, ANIMAL; HEART FAILURE; HUMANS; MICE; MICE, KNOCKOUT; RECEPTORS, ADRENERGIC, BETA;

EID: 37249093024     PISSN: 00316768     EISSN: 14322013     Source Type: Journal    
DOI: 10.1007/s00424-007-0324-1     Document Type: Review

References (64)

1. Ahlquist RP (1948) A study of the adrenotropic receptors. Am J Physiol 153:586-600
2. Ahlquist RP (1967) Development of the concept of alpha and beta adrenotropic receptors. Ann NY Acad Sci 139:549-552
3. Azevedo ER, Parker JD (1999) Parasympathetic control of cardiac sympathetic activity: normal ventricular function versus congestive heart failure. Circulation 100:274-279
4. Bittner HB, Chen EP, Milano CA, Lefkowitz RJ, Van Trigt P (1997) Functional analysis of myocardial performance in murine hearts overexpressing the human beta 2-adrenergic receptor. J Mol Cell Cardiol 29:961-967
5. Bleumink GS, Knetsch AM, Sturkenboom MC et al (2004) Quantifying the heart failure epidemic: prevalence, incidence rate, lifetime risk and prognosis of heart failure The Rotterdam Study. Eur Heart J 25:1614-1619
6. Bond RA, Leff P, Johnson TD et al (1995) Physiological effects of inverse agonists in transgenic mice with myocardial overexpression of the beta 2-adrenoceptor. Nature 374:272-276
7. Bristow MR, Ginsburg R, Umans V et al (1986) Beta 1- and beta 2-adrenergic-receptor subpopulations in nonfailing and failing human ventricular myocardium: coupling of both receptor subtypes to muscle contraction and selective beta 1-receptor down-regulation in heart failure. Circ Res 59:297-309
8. Brixius K, Bloch W, Pott C et al (2004) Mechanisms of beta 3-adrenoceptor-induced eNOS activation in right atrial and left ventricular human myocardium. Br J Pharmacol 143:1014-1022
9. Brodde OE, Michel MC (1999) Adrenergic and muscarinic receptors in the human heart. Pharmacol Rev 51:651-690
10. Bylund DB, Eikenberg DC, Hieble JP et al (1994) International Union of Pharmacology nomenclature of adrenoceptors. Pharmacol Rev 46:121-136
11. Calaghan SC, White E, Colyer J (1998) Co-ordinated changes in cAMP, phosphorylated phospholamban, Ca2+ and contraction following beta-adrenergic stimulation of rat heart. Pflugers Arch 436:948-956
12. Chruscinski AJ, Rohrer DK, Schauble E, Desai KH, Bernstein D, Kobilka BK (1999) Targeted disruption of the beta2 adrenergic receptor gene. J Biol Chem 274:16694-16700
13. Cleland JG, Khand A, Clark A (2001) The heart failure epidemic: exactly how big is it? Eur Heart J 22:623-626
14. Cohn JN, Levine TB, Olivari MT et al (1984) Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 311:819-823
15. Cross HR, Steenbergen C, Lefkowitz RJ, Koch WJ, Murphy E (1999) Overexpression of the cardiac beta(2)-adrenergic receptor and expression of a beta-adrenergic receptor kinase-1 (betaARK1) inhibitor both increase myocardial contractility but have differential effects on susceptibility to ischemic injury. Circ Res 85:1077-1084
16. Dorn GW 2nd, Tepe NM, Lorenz JN, Koch WJ, Liggett SB (1999) Low- and high-level transgenic expression of beta2-adrenergic receptors differentially affect cardiac hypertrophy and function in Galphaq-overexpressing mice. Proc Natl Acad Sci USA 96:6400-6405
17. Du XJ, Vincan E, Woodcock DM, Milano CA, Dart AM, Woodcock EA (1996) Response to cardiac sympathetic activation in transgenic mice overexpressing beta 2-adrenergic receptor. Am J Physiol 271:H630-H636
18. Du XJ, Autelitano DJ, Dilley RJ, Wang B, Dart AM, Woodcock EA (2000) beta(2)-adrenergic receptor overexpression exacerbates development of heart failure after aortic stenosis. Circulation 101:71-77
19. Du XJ, Gao XM, Jennings GL, Dart AM, Woodcock EA (2000) Preserved ventricular contractility in infarcted mouse heart overexpressing beta(2)-adrenergic receptors. Am J Physiol Heart Circ Physiol 279:H2456-H2463
20. Du XJ, Gao XM, Wang B, Jennings GL, Woodcock EA, Dart AM (2000) Age-dependent cardiomyopathy and heart failure phenotype in mice overexpressing beta(2)-adrenergic receptors in the heart. Cardiovasc Res 48:448-454
21. Eckberg DL, Drabinsky M, Braunwald E (1971) Defective cardiac parasympathetic control in patients with heart disease. N Engl J Med 285:877-883
22. Emorine LJ, Marullo S, Briend-Sutren MM et al (1989) Molecular characterization of the human beta 3-adrenergic receptor. Science 245:1118-1121
23. Engelhardt S, Hein L, Wiesmann F, Lohse MJ (1999) Progressive hypertrophy and heart failure in beta1-adrenergic receptor transgenic mice. Proc Natl Acad Sci USA 96:7059-7064
24. Engelhardt S, Boknik P, Keller U, Neumann J, Lohse MJ, Hein L (2001) Early impairment of calcium handling and altered expression of junctin in hearts of mice overexpressing the beta1-adrenergic receptor. FASEB J 15:2718-2720
25. Engelhardt S, Hein L, Dyachenkow V, Kranias EG, Isenberg G, Lohse MJ (2004) Altered calcium handling is critically involved in the cardiotoxic effects of chronic beta-adrenergic stimulation. Circulation 109:1154-1160
26. Freestone NS, Ribaric S, Scheuermann M, Mauser U, Paul M, Vetter R (2000) Differential lusitropic responsiveness to beta-adrenergic stimulation in rat atrial and ventricular cardiac myocytes. Pflugers Arch 441:78-87
27. Gauthier C, Tavernier G, Charpentier F, Langin D, Le Marec H (1996) Functional beta3-adrenoceptor in the human heart. J Clin Invest 98:556-562
28. Gauthier C, Leblais V, Kobzik L et al (1998) The negative inotropic effect of beta3-adrenoceptor stimulation is mediated by activation of a nitric oxide synthase pathway in human ventricle. J Clin Invest 102:1377-1384
29. Jessup M, Brozena S (2003) Heart failure. N Engl J Med 348:2007-2018
30. Kaumann AJ, Preitner F, Sarsero D, Molenaar P, Revelli JP, Giacobino JP (1998) (-)-CGP 12177 causes cardiostimulation and binds to cardiac putative beta 4-adrenoceptors in both wild-type and beta 3-adrenoceptor knockout mice. Mol Pharmacol 53:670-675
31. Kaumann AJ, Engelhardt S, Hein L, Molenaar P, Lohse M (2001) Abolition of (-)-CGP 12177-evoked cardiostimulation in double beta1/beta2-adrenoceptor knockout mice. Obligatory role of beta1-adrenoceptors for putative beta4-adrenoceptor pharmacology. Naunyn Schmiedebergs Arch Pharmacol 363:87-93
32. Kilts JD, Gerhardt MA, Richardson MD et al (2000) Beta(2)-adrenergic and several other G protein-coupled receptors in human atrial membranes activate both G(s) and G(i). Circ Res 87:705-709
33. Kohout TA, Takaoka H, McDonald PH et al (2001) Augmentation of cardiac contractility mediated by the human beta(3)-adrenergic receptor overexpressed in the hearts of transgenic mice. Circulation 104:2485-2491
34. Liggett SB, Tepe NM, Lorenz JN et al (2000) Early and delayed consequences of beta(2)-adrenergic receptor overexpression in mouse hearts: critical role for expression level. Circulation 101:1707-1714
35. Mackenzie E, Standen NB (1980) The postnatal development of adrenoceptor responses in isolated papillary muscles from rat. Pflugers Arch 383:185-187
36. MacLennan DH, Kranias EG (2003) Phospholamban: a crucial regulator of cardiac contractility. Nat Rev, Mol Cell Biol 4:566-577
37. Milano CA, Allen LF, Rockman HA et al (1994) Enhanced myocardial function in transgenic mice overexpressing the beta 2-adrenergic receptor. Science 264:582-586
38. Milano CA, Allen LF, Dolber PC et al (1995) Marked enhancement in myocardial function resulting from overexpression of a human beta-adrenergic receptor gene. J Thorac Cardiovasc Surg 109:236-241
39. Muller FU, Kirchhefer U, Begrow F, Reinke U, Neumann J, Schmitz W (2002) Junctional sarcoplasmic reticulum transmembrane proteins in the heart. Basic Res Cardiol 97(Suppl 1):I52-I55
40. Port JD, Bristow MR (2001) Altered beta-adrenergic receptor gene regulation and signaling in chronic heart failure. J Mol Cell Cardiol 33:887-905
41. Porter TR, Eckberg DL, Fritsch JM et al (1990) Autonomic pathophysiology in heart failure patients. Sympathetic-cholinergic interrelations. J Clin Invest 85:1362-1371
42. Pott C, Brixius K, Bundkirchen A et al (2003) The preferential beta3-adrenoceptor agonist BRL 37344 increases force via beta1-/beta2- adrenoceptors and induces endothelial nitric oxide synthase via beta3-adrenoceptors in human atrial myocardium. Br J Pharmacol 138:521-529
43. Revelli JP, Preitner F, Samec S et al (1997) Targeted gene disruption reveals a leptin-independent role for the mouse beta3-adrenoceptor in the regulation of body composition. J Clin Invest 100:1098-1106
44. Rockman HA, Hamilton RA, Jones LR, Milano CA, Mao L, Lefkowitz RJ (1996) Enhanced myocardial relaxation in vivo in transgenic mice overexpressing the beta2-adrenergic receptor is associated with reduced phospholamban protein. J Clin Invest 97:1618-1623
45. Rohrer DK, Desai KH, Jasper JR et al (1996) Targeted disruption of the mouse beta1-adrenergic receptor gene: developmental and cardiovascular effects. Proc Natl Acad Sci USA 93:7375-7380
46. Rohrer DK, Schauble EH, Desai KH, Kobilka BK, Bernstein D (1998) Alterations in dynamic heart rate control in the beta 1-adrenergic receptor knockout mouse. Am J Physiol 274:H1184-H1193
47. Rohrer DK, Chruscinski A, Schauble EH, Bernstein D, Kobilka BK (1999) Cardiovascular and metabolic alterations in mice lacking both beta1- and beta2-adrenergic receptors. J Biol Chem 274:16701-16708
48. Satwani S, Dec GW, Narula J (2004) Beta-adrenergic blockers in heart failure: review of mechanisms of action and clinical outcomes. J Cardiovasc Pharmacol Ther 9:243-255
49. Schwarz B, Percy E, Gao XM, Dart AM, Richardt G, Du XJ (2003) Altered calcium transient and development of hypertrophy in beta2-adrenoceptor overexpressing mice with and without pressure overload. Eur J Heart Fail 5:131-136
50. Schwinger RH, Bohm M, Erdmann E (1990) Evidence against spare or uncoupled beta-adrenoceptors in the human heart. Am Heart J 119:899-904
51. Schwinger RH, Bohm M, Schmidt U et al (1995) Unchanged protein levels of SERCA II and phospholamban but reduced Ca2+ uptake and Ca(2+)-ATPase activity of cardiac sarcoplasmic reticulum from dilated cardiomyopathy patients compared with patients with nonfailing hearts. Circulation 92:3220-3228
52. Sheridan DJ, Autelitano DJ, Wang B, Percy E, Woodcock EA, Du XJ (2000) Beta(2)-adrenergic receptor overexpression driven by alpha-MHC promoter is downregulated in hypertrophied and failing myocardium. Cardiovasc Res 47:133-141
53. Steinberg SF (1999) The molecular basis for distinct beta-adrenergic receptor subtype actions in cardiomyocytes. Circ Res 85:1101-1111
54. Stroe AF, Gheorghiade M (2004) Carvedilol: beta-blockade and beyond. Rev Cardiovasc Med 5(Suppl 1):S18-S27
55. Susulic VS, Frederich RC, Lawitts J et al (1995) Targeted disruption of the beta 3-adrenergic receptor gene. J Biol Chem 270:29483-29492
56. Tavernier G, Toumaniantz G, Erfanian M et al (2003) beta3-Adrenergic stimulation produces a decrease of cardiac contractility ex vivo in mice overexpressing the human beta3-adrenergic receptor. Cardiovasc Res 59:288-296
57. Varghese P, Harrison RW, Lofthouse RA, Georgakopoulos D, Berkowitz DE, Hare JM (2000) beta(3)-adrenoceptor deficiency blocks nitric oxide-dependent inhibition of myocardial contractility. J Clin Invest 106:697-703
58. Vrydag W, Michel MC (2007) Tools to study beta3-adrenoceptors. Naunyn Schmiedebergs Arch Pharmacol 374:385-398
59. Wagner KD, Geil D, Schimke I et al (1998) Decreased susceptibility of contractile function to hypoxia/reoxygenation in chronic infarcted rat hearts. J Mol Cell Cardiol 30:2341-2353
60. Wenzel-Seifert K, Seifert R (2000) Molecular analysis of beta(2)-adrenoceptor coupling to G(s)-, G(i)-, and G(q)-proteins. Mol Pharmacol 58:954-966
61. Xiao RP, Zhu W, Zheng M et al (2004) Subtype-specific beta-adrenoceptor signaling pathways in the heart and their potential clinical implications. Trends Pharmacol Sci 25:358-365
62. Zhou YY, Song LS, Lakatta EG, Xiao RP, Cheng H (1999) Constitutive beta2-adrenergic signalling enhances sarcoplasmic reticulum Ca2+ cycling to augment contraction in mouse heart. J Physiol (Lond) 521(Pt 2):351-361
63. Zhu WZ, Zheng M, Koch WJ, Lefkowitz RJ, Kobilka BK, Xiao RP (2001) Dual modulation of cell survival and cell death by beta(2)-adrenergic signaling in adult mouse cardiac myocytes. Proc Natl Acad Sci USA 98:1607-1612
64. Ziskoven C, Grafweg S, Bölck B et al (2007) Increased Ca2+ sensitivity and protein expression of SERCA 2a in situations of chronic beta3-adrenoceptor deficiency. Pflugers Arch 453:443-453